
AstraZeneca PLC
AZNHealthcare|Drug Manufacturers - General|GB
$186.43
-0.42 (-0.22%)
DCF Value
$500.17
Graham Number
$72.85
Cash / Share
$5.23
Next Earnings Report
Feb 9, 2027
EPS est. $2.32 · Revenue est. $16.59B
Financing Filings (last 12 months)
2
Shelf registrations / offering prospectuses — latest Feb 27, 2026 (424B2). Possible dilution.
Upcoming Data Readouts (61)
Dec 2026
Est. completion
Asthma
PROPULSION SANTE: Inflammometry to Improve the Diagnostic Trajectory in Situations of Suspected Asthma in Children and Adults
NCT06981169n=1,500
Dec 2026
Est. completion
Dec 2026
Est. completion
NAPreventable Disease, Vaccine
Addressing Unfunded Vaccines Through a Co-payment Mechanism in Pharmacies
NCT06489964n=600
Dec 2026
Est. completion
Non-squamous Non-Small Cell Lung Cancer
RACE-2L: Real-World Assessment of Clinical Practice and Outcomes in Non-squamous NSCLC After Failure of Platinum-based Chemotherapy in Brazil
NCT06491862n=250
Dec 2026
Est. completion
Heart Diseases
Real-world Study on Dapagliflozin Usage in Patients With Heart Failure (HF) in Germany
NCT06336330n=831
Dec 2026
Est. completion
Jan 2027
Est. completion
P2Extrahepatic Cholangiocarcinoma
Durvalumab + Intraductal Radiofrequency Ablation (ID-RFA) in Extra- and Intrahepatic Cholangiocarcinoma
NCT06440993n=42
Jan 2027
Est. completion
P3Cardiovascular Disease
A Phase III Study to Assess the Effect of AZD0780 on LDL-C in Patients With Clinical ASCVD or at Risk for a First ASCVD Event
NCT07000123n=3,103
Jan 2027
Est. completion
P1P2Diffuse Large B-Cell Lymphoma
Acalabrutinib Maintenance for the Treatment of Patients With Large B-cell Lymphoma
NCT05256641n=24
Feb 2027
Est. completion
P3Lymphoma, Mantle Cell
A Study of BR Alone Versus in Combination With Acalabrutinib in Subjects With Previously Untreated MCL
NCT02972840n=635
Mar 2027
Est. completion
P1P2Staphylococcus Aureus
A Study to Evaluate AZD7760 Safety and Pharmacokinetics in Healthy Adults (Phase I) and Adults With End-stage Kidney Disease on Hemodialysis With a Central Venous Catheter (Phase IIa)
NCT06749457n=242
Mar 2027
Est. completion
Apr 2027
Est. completion
P2Clostridioides Difficile Infection
Prevention of Recurrent C. Difficile Infection Study With AZD5148 Monoclonal Antibody
NCT07285213n=230
Jun 2027
Est. completion
Jun 2027
Est. completion
Severe Asthma
Clinical and demOgRaphic Features of Patients With Uncontrolled Severe Asthma in Russia (CORSAR)
NCT06472310n=5,000
Jul 2027
Est. completion
P3Kidney Disease, Chronic
The RENAL LIFECYCLE Trial: A RCT to Assess the Effect of Dapagliflozin on Renal and Cardiovascular Outcomes in Patients With Severe CKD
NCT05374291n=1,750
Sep 2027
Est. completion
Chronic Obstructive Pulmonary Disease
Study of Clinical and Patient-reported Outcomes in Adults With Moderate to Severe COPD Treated With Breztri/Trixeo
NCT07069829n=1,400
Oct 2027
Est. completion
P2Non-Small Cell Lung Cancer (NSCLC)
A Study to Investigate Safety and Efficacy of Osimertinib and Amivantamab in Participants With Non-small Cell Lung Cancer With Common Epidermal Growth Factor Receptor Mutations
NCT05801029n=60
Oct 2027
Est. completion
Nov 2027
Est. completion
P3Viral Lung Infection and Acute Respiratory Failure
Efficacy and Safety of Tozorakimab in Patients Hospitalised for Viral Lung Infection Requiring Supplemental Oxygen
NCT05624450n=3,527
Awaiting Results (22)
Trials past primary completion date but still active — data readout may be imminent.
Oct 2026
P2
Trimodality Therapy With/Out Durvalumab to Treat Patients With Muscle-Invasive Bladder Cancer
NCT03768570Oct 2026
P2
Study of Novel Immunomodulators as Monotherapy and in Combination With Anticancer Agents in Participants With Advanced Hepatobiliary Cancer
NCT05775159Oct 2026
P2
This is a Multi-centre, Multi-drug, Platform Study in Chinese Participants Living With Obesity / Overweight
NCT07017179Oct 2026
P1P2
A Study to Characterize the Safety and Immunogenicity of AZD6489 in Participants 60 Years of Age and Older (ARIES)
NCT07717840Sep 2026
P2
AZD1775 in Women With Recurrent or Persistent Uterine Serous Carcinoma or Uterine Carcinosarcoma
NCT03668340Jul 2026
P3
A Phase III, Randomised Study of Adjuvant Dato-DXd in Combination With Rilvegostomig or Rilvegostomig Monotherapy Versus Standard of Care, Following Complete Tumour Resection, in Participants With Stage I Adenocarcinoma NSCLC Who Are ctDNA-positive or Have High-risk Pathological Features
NCT06564844Jun 2026
P3
Study of Durvalumab Given With Chemotherapy, Durvalumab in Combination With Tremelimumab Given With Chemotherapy, or Chemotherapy in Patients With Unresectable Urothelial Cancer
NCT03682068Mar 2026
P3
Treatment Combination of Durvalumab, Tremelimumab and Enfortumab Vedotin or Durvalumab and Enfortumab Vedotin in Patients With Muscle Invasive Bladder Cancer Ineligible to Cisplatin or Who Refuse Cisplatin
NCT04960709Jan 2026
Prospective Cohort of Locally Advanced and Metastatic Non-Small Cell Lung Cancer Patients With Activating EGFR Mutations
NCT05103605May 2025
P3
A Phase III Study to Evaluate the Efficacy and Safety of Benralizumab in Patients With Hypereosinophilic Syndrome (HES)
NCT04191304Recent Press Releases
AstraZeneca results: 9M and Q3 2026
Oct 30, 2026 · Business Wire
AstraZeneca and Mark-Paul Gosselaar Launch Meet Your Mark to Raise Awareness of Cancer Biomarker Testing
Oct 28, 2026 · Business Wire
Breast Cancer Canada and AstraZeneca Canada Advance Next-Generation Survivorship Research
Oct 27, 2026 · Business Wire
TAGRISSO® (osimertinib) plus savolitinib reduced the risk of disease progression or death by 45% and the risk of death by 32% in MET-driven EGFR-mutated lung cancer after progression on TAGRISSO
Oct 25, 2026 · Business Wire
Perioperative IMFINZI® (durvalumab) plus neoadjuvant enfortumab vedotin reduced risk of recurrence by 49% and risk of death by 42% in muscle-invasive bladder cancer
Oct 24, 2026 · Business Wire
ZEGFROVY® (sunvozertinib) now available in the US for patients with previously treated non-small cell lung cancer with EGFR exon 20 insertion mutations
Oct 22, 2026 · Business Wire
AstraZeneca to present overall survival data from four pivotal Phase III trials in Presidential Symposia at ESMO 2026 featuring Sone-Ve, IMFINZI® (durvalumab), TAGRISSO® (osimertinib) and savolitinib
Oct 19, 2026 · Business Wire
Guardant Health Announces Approval in Europe of Guardant360® CDx as Companion Diagnostic for AstraZeneca's ETCAMAH™ (camizestrant) in Advanced ER-positive Breast Cancer
Oct 8, 2026 · Business Wire
SEC Filings (245)
Last two years from EDGAR. Insider Form 4s are on the Ownership tab.
| Filed | Form | What it is | Links |
|---|---|---|---|
| Nov 2, 2026 | 6-K | Foreign issuer report | DocumentIndex |
| Nov 2, 2026 | 6-K | Foreign issuer report | DocumentIndex |
| Oct 30, 2026 | 6-K | Foreign issuer report | DocumentIndex |
| Oct 27, 2026 | 6-K | Foreign issuer report | DocumentIndex |
| Oct 22, 2026 | 6-K | Foreign issuer report | DocumentIndex |
| Oct 5, 2026 | 6-K | Foreign issuer report | DocumentIndex |
| Oct 2, 2026 | 6-K | Foreign issuer report | DocumentIndex |
| Oct 1, 2026 | 6-K | Foreign issuer report | DocumentIndex |
| Oct 1, 2026 | 6-K | Foreign issuer report | DocumentIndex |
| Sep 29, 2026 | 6-K | Foreign issuer report | DocumentIndex |
| Sep 23, 2026 | 6-K | Foreign issuer report | DocumentIndex |
| Sep 21, 2026 | 6-K | Foreign issuer report | DocumentIndex |
| Sep 21, 2026 | 6-K | Foreign issuer report | DocumentIndex |
| Sep 18, 2026 | 6-K | Foreign issuer report | DocumentIndex |
| Sep 15, 2026 | 6-K | Foreign issuer report | DocumentIndex |
| Sep 15, 2026 | 6-K | Foreign issuer report | DocumentIndex |
| Sep 14, 2026 | 6-K | Foreign issuer report | DocumentIndex |
| Sep 8, 2026 | 6-K | Foreign issuer report | DocumentIndex |
| Sep 8, 2026 | 6-K | Foreign issuer report | DocumentIndex |
| Sep 1, 2026 | 6-K | Foreign issuer report | DocumentIndex |
| Sep 1, 2026 | 6-K | Foreign issuer report | DocumentIndex |
| Sep 1, 2026 | 6-K | Foreign issuer report | DocumentIndex |
| Sep 1, 2026 | 6-K | Foreign issuer report | DocumentIndex |
| Sep 1, 2026 | 6-K | Foreign issuer report | DocumentIndex |
| Sep 1, 2026 | 6-K | Foreign issuer report | DocumentIndex |
| Sep 1, 2026 | 6-K | Foreign issuer report | DocumentIndex |
| Aug 27, 2026 | 6-K | Foreign issuer report | DocumentIndex |
| Aug 25, 2026 | 6-K | Foreign issuer report | DocumentIndex |
| Aug 19, 2026 | 6-K | Foreign issuer report | DocumentIndex |
| Aug 17, 2026 | 6-K | Foreign issuer report | DocumentIndex |
| Aug 17, 2026 | 6-K | Foreign issuer report | DocumentIndex |
| Aug 17, 2026 | 6-K | Foreign issuer report | DocumentIndex |
| Aug 3, 2026 | 6-K | Foreign issuer report | DocumentIndex |
| Aug 3, 2026 | 6-K | Foreign issuer report | DocumentIndex |
| Jul 31, 2026 | 6-K | Foreign issuer report | DocumentIndex |
| Jul 27, 2026 | 6-K | Foreign issuer report | DocumentIndex |
| Jul 27, 2026 | 6-K | Foreign issuer report | DocumentIndex |
| Jul 27, 2026 | 6-K | Foreign issuer report | DocumentIndex |
| Jul 23, 2026 | 6-K | Foreign issuer report | DocumentIndex |
| Jul 14, 2026 | 6-K | Foreign issuer report | DocumentIndex |